The Immunobiology Program aims to: 1) Understand the fundamental aspects of immune biology, including activation, differentiation, inactivation, and transformation as these relate to cancer; 2) Forge a comprehensive understanding of tumor immune surveillance using state-of-the art in vitro, animal model, and human experimental systems; and 3) Translate novel clinical strategies for immunotherapy of cancer by the design, implementation, and analysis of proof-of-concept human clinical trials. Established in 1974, this Research Program received ?Outstanding? merit at the time of the last CCSG renewal application. The Program is Co- Led by Robert Vonderheide, MD, DPhil, an expert in tumor immunology and immunotherapy, and Warren Pear, MD, PhD, an expert in the molecular biology of leukocyte development and malignant transformation. Drs. Vonderheide and Pear are experienced, NCI-funded investigators who are highly collaborative and whose research interests span the realm of basic and translational science. There are 34 Program members from 10 departments and four schools with long-standing intra- and inter-Programmatic collaborations spanning the Basic as well as Clinical Programs. Through these interactions, the members' collective expertise serves as a rich resource for the pursuit of interdisciplinary approaches to fundamental questions about the immunobiology and immunotherapy of cancer. Members include national leaders in basic immunology, tumor immunobiology and translational immunotherapy. The Program Co-Leaders facilitate interactions through multiple weekly seminars and meetings, promotion of collaborative grants and projects, an annual research retreat, Pilot Project grants, and training programs. During the current project period, Program Leaders recruited new members, expanded important forums, facilitated new collaborative grants, initiated new ACC-wide initiatives, and were actively involved in decisions regarding new and existing Shared Resources. Currently, Program members have $20.6M in research grant funding (annual direct costs), of which $11.3M is peer-reviewed and $2.2M is NCI-funded. During the current project period, Program members published 421 cancer-related publications, many of which are in top journals in the field. Of these, 17% are intra-Programmatic, 24% are inter-Programmatic, and 29% are multi-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-43
Application #
9618139
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5

Showing the most recent 10 out of 1047 publications